Search

everythinglearnresearchcommunity

for

Search:↓

Selumetinib causes skin and hair side effects in kids with NF1, affecting treatment and quality of life.

Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.

Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.

The treatment improved survival and controlled cancer spread but required managing side effects like rashes.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.

Tofacitinib helped a woman regrow hair with no major side effects.

Targeted therapy for skin cancer is complex due to the role of the hedgehog pathway in both cancer and hair growth.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.

A topical BRAF inhibitor, vemurafenib, can speed up wound healing and promote hair growth, especially in diabetic patients.

Certain cancer drugs can cause skin issues like rashes and itching.

BKN-1 antibody targets specific keratin in basal cell epithelioma and normal skin basal cells.

Different tumor cells in one basal cell carcinoma can cause mixed treatment responses, suggesting personalized treatment is needed.

Tofacitinib taken by mouth helps treat hair loss in children.

Low-dose sorafenib can cause severe facial acne, treatable with topical medication.

New treatments targeting the Hedgehog pathway can help treat advanced skin cancer but may have side effects and their effectiveness in early stages is unknown.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

The review suggests that while many AKR1C3 inhibitors show promise for treating certain cancers, more research is needed to confirm their effectiveness in humans.

Axitinib treatment turned a man's grey hair back to black.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.

4-O-Methylhonokiol helps protect skin cells from growth-stopping effects of a protein by regulating growth-related pathways.

XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.

MOF controls skin development by regulating genes for mitochondria and cilia.

Porocarcinoma generally has low rates of recurrence, spread to lymph nodes, and death.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Biobran MGN-3 reduces chemotherapy side effects and improves quality of life for breast cancer patients.

Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.